Potent and highly selective ROCK inhibitor (IC50
values are 0.6 and 1.1 nM for ROCK1 and ROCK2, respectively). Exhibits >200-fold selectivity over TRK and FLT3 receptors, and >900-fold selectivity over a panel of other kinases and cardiovascular relevent enzymes and receptors. Reduces blood pressure in normotensive and hypertensive rats. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.
Kast et al.
Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension.
Dahal et al.